Eli Lilly (LLY) Skyrockets as Profits Soar 95%

We recently published 10 Stocks With Monster Gains. Eli Lilly and Company (NYSE:LLY) was one of the top performers on Wednesday.

Eli Lilly soared by 10.33 percent on Wednesday to close at $1,107.12 apiece after profits last year nearly doubled on the back of strong sales from Zepbound and Mounjaro, alongside a 23 percent revenue growth guidance for 2026.

In an updated report on the same day, Eli Lilly and Company (NYSE:LLY) said that net income last year soared by 95 percent to $20.6 billion from $10.59 billion in 2024, as revenues surged by 45 percent to $65 billion from $45 billion.

In the fourth quarter alone, net income jumped by 50 percent to $6.6 billion from $4.4 billion in the same period a year earlier, while revenues increased by 43 percent to $19.29 billion from $13.5 billion, thanks to its weight loss and obesity drugs Zepbound and Mounjaro, as well as a 46 percent jump in volumes which offset the 5 percent lower prices.

Encouraged by the results, Eli Lilly and Company (NYSE:LLY) has set an $80 billion to $83 billion revenue growth guidance for 2026, or an implied growth of 23 to 28 percent from last year’s revenues. Earnings per share were pegged at $33.50 to $35.

Eli Lilly and Company (NYSE:LLY) received a maintained price target of $1,150 from Goldman Sachs, alongside a “buy” recommendation.

While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.